Sarepta Therapeutics announced it has laid off more than one-third of its workforce, a drastic cost-cutting move following ...

Shipments will halt by close of business Tuesday evening, the company said. Sarepta had initially rejected the agency’s ...

Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.

Sarepta Therapeutics’ stock was soaring Tuesday after the FDA recommended lifting the pause on the company’s Duchenne ...

ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age. For patients who are ambulatory and have a confirmed mutation in the DMD gene.

A patient has died after receiving Sarepta Therapeutics’ approved gene therapy for Duchenne muscular dystrophy — the second fatality reported by the company in the past three months.

Cambridge-based drugmaker Sarepta Therapeutics said it would charge $3.2 million for the one-time treatment, slightly less than a $3.5 million gene therapy for hemophilia launched last year.

Sarepta Therapeutics, Inc. Investors: Ian Estepan, 617-274-4052 iestepan@sarepta.com Media: Tracy Sorrentino, 617-301-8566 tsorrentino@sarepta.com Source: Sarepta Therapeutics, Inc.

The company said its drug, Elevidys, was given traditional approval for patients who are at least 4 years old and suffer from Duchenne muscular dystrophy (DMD) with a confirmed mutation in the DMD ...

Sarepta Therapeutics, Inc. had $2 billion in cash reserves at the end of 2022, which is expected to last at least for the next two years. The operating cash burn was $210 million in Q1 this year.

Jefferies has initiated coverage of Sarepta Therapeutics (NASDAQ:SRPT) at buy saying its Duchenne muscular dystrophy franchise represents a $4B+ opportunity, as well as a strong pipeline and ...

Healthcare Sarepta Therapeutics: Backing A Cure For Duchenne Muscular Dystrophy Aug. 22, 2017 9:13 AM ETSarepta Therapeutics, Inc. (SRPT) StockBIIB, PFE, SRPT13 Comments Karim Henide 241Followers ...